How RWE can support drug development during COVID-19 and beyond
The COVID-19 pandemic introduced novel challenges for global biopharma organizations, as many...
The COVID-19 pandemic introduced novel challenges for global biopharma organizations, as many...
COVID-19 has heightened the need for an expanded understanding of clinical trial populations and...
As the new year begins, many patients refocus on weight management and long-term health goals. At the same time, GLP-1 drugs have reshaped the obesity treatment landscape.1,2 With semaglutide and other GLP-1 medications in high demand for weight loss...